Details of the Drug

General Information of Drug (ID: DM0K4WQ)

Drug Name

PF-07261271

Indication

Disease Entry	ICD 11	Status	REF
Inflammatory bowel disease	DD72	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Antibody

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interleukin-12 beta (IL12B)	TTGW72V	IL12B_HUMAN	Not Available	[2]
Vascular endothelial cell growth inhibitor (TNFSF15)	TTEST6I	TNF15_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Inflammatory bowel disease

ICD Disease Classification

DD72

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Interleukin-12 beta (IL12B)	DTT	IL12B	1.08E-01	0.13	0.17

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT05536440) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR OPEN, PLACEBO CONTROLLED, DOSE ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE INTRAVENOUS AND MULTIPLE SUBCUTANEOUS AND INTRAVENOUS DOSES OF PF-07261271 IN HEALTHY PARTICIPANTS. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Pfizer